ATOS — Atossa Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Atossa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 136 | 111 | 88.5 | 71.1 | 41.3 |
| Net Total Receivables | 1.07 | 0.743 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 141 | 118 | 92.2 | 74.5 | 45.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.02 | — | — | — | — |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 141 | 124 | 96.3 | 76.4 | 47.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.13 | 5.57 | 5.24 | 4.97 | 8.26 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 3.13 | 5.57 | 5.24 | 4.97 | 8.26 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 138 | 118 | 91 | 71.5 | 39.4 |
| Total Liabilities & Shareholders' Equity | 141 | 124 | 96.3 | 76.4 | 47.6 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |